Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 81

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 81
---
 in-licensing transactions, or through our internal capabilities.
Our acquisition and in-licensing efforts focus on identifying assets in development by third parties across a diverse range
of therapeutic areas. Our strategy often entails designing optimal, efficient studies that result in quick “go/no-go” decisions
when deciding whether or how to proceed with future development for a given asset. We may decide to proceed with the development of a
drug candidate on this basis and later determine that the more costly and time intensive trials do not support the initial value the product
was thought to hold. Even if a product candidate does prove to be valuable, its value may be less than anticipated at the time of initial
investment. We may also face competition for attractive investment opportunities. A number of entities compete with us for such opportunities,
many of which have considerably greater financial and technical resources. If we are unable to identify a sufficient number of such product
candidates, or if the product candidates that we identify do not prove to be as valuable as anticipated, we will not be able to generate
returns and implement our investment strategy and our business and results of operations may suffer materially.

We currently have no marketing and sales organization for pharmaceutical
products and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these
capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and
sell our pharmaceutical products, we may not be able to generate pharmaceutical product revenue.

We have no internal sales, marketing or distribution capabilities for
pharmaceutical products (one subsidiary markets and sells medical products and devices), nor have we commercialized a product. If any
of our pharmaceutical product candidates ultimately receive regulatory approval, we expect to establish either an internal or external
pharmaceutical marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each
such product in applicable major markets, which will be expensive and, to the extent we establish such an organization in-house, time
consuming. We have no prior experience as a company in the marketing, sale and distribution of pharmaceutical products and there are significant
risks involved in establishing or managing a sales organization, including our ability to hire, retain and incentivize qualified individuals,
generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed
sales and marketing team. Any failure or delay in the development of our internal or external pharmaceutical sales, marketing